Financials reflect increased investment
RUA Life Sciences interim results demonstrated the continued investment in the business and its new...
Read moreStrong performance and improving outlook
Benchmark Holdings’ FY21 and particularly its Q4 (July to September) results confirmed the strong...
Read moreBuilding further share in key markets
The first half result was impressive with 39% revenue growth and a pleasing 16% operating margin...
Read moreSolid update amidst pandemic uncertainty
In a half-year trading update to 30 Nov 21 (H1 22), Time Finance has reported positive loan...
Read moreFurther strong momentum in PM division reported
The consistent performance by R&Q’s Program Management (PM) division puts it comfortably on track...
Read moreRegulatory hiccup
RUA Life Sciences have announced a regulatory update on the 510(k) submission for its vascular...
Read more
Strong H1 growth and even better profits
Half-year results to 30 Sept 21 (H1 22) show continuing strength in LendInvest’s growth and...
Read more
Leaving the competition behind
Maiden H1 results from Supreme confirm strong progress driven by organic growth, bolt-on...
Read more
Another leap in scale and outlook still strong
FY21 (to 30 Sept) saw Impax continuing to scale at a pace unmatched by any UK-listed asset manager,...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
